Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Taking the Next Step Insulin resistance sits at the core of many metabolic problems, and addressing it can produce improvements that ripple across multiple aspects of health
(Empagliflozin is one of the active drugs in Synjardy.) Its important to note that animal studies dont always predict what will happen in people
Medically Supervised Care Our platform is a user-friendly and supportive space where individuals receive personalized, medically supervised careall designed to make sustainable weight loss attainable and tailored to the individual
Flavonoids can further be classified into anthocyanins, flavonols, flavanols, flavanones, and isoflavones, each sourced from various plants such as berries, grapes, tea, and soybeans
If your aim is to sustain fat loss while reducing side effects, focus on three habits right away: protect hydration and protein intake around meals, follow a slow titration schedule that stays in place when mild symptoms appear, and keep a record of every symptom and missed dose for at least the first 12 weeks